

Head And Neck Cancer - Pipeline Review, H1 2020

<https://marketpublishers.com/r/HA9E6D26841EN.html>

Date: April 2020

Pages: 2943

Price: US\$ 2,500.00 (Single User License)

ID: HA9E6D26841EN

Abstracts

Head And Neck Cancer - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer - Pipeline Review, H1 2020, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape.

Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by

Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 22, 185, 179, 1, 8, 113, 24 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 10, 11, 1, 21, 4 and 1 molecules, respectively.

Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics

based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Head And Neck Cancer - Overview

Head And Neck Cancer - Therapeutics Development

Head And Neck Cancer - Therapeutics Assessment

Head And Neck Cancer - Companies Involved in Therapeutics Development

Head And Neck Cancer - Drug Profiles

Head And Neck Cancer - Dormant Projects

Head And Neck Cancer - Discontinued Products

Head And Neck Cancer - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Head And Neck Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..8), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..9), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..10), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..11), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..12), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..13), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..14), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..15), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..16), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..17), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1),
H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2),
H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..6), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..7), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Head And Neck Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

2A Pharma AB
4D Pharma Plc
4SC AG
A2 Biotherapeutics Inc
Aadi Bioscience Inc
AbbVie Inc
Abion Inc
ABL Bio Inc
Acepodia Biotech Inc
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Admedus Ltd
Aduro BioTech Inc
Advaxis Inc
Advenchen Laboratories LLC
Adze Biotechnology Inc
Affimed GmbH
Agenus Inc
Akeso Biopharma Inc
Alkermes Plc

Alligator Bioscience AB
Alphamab Oncology
ALX Oncology Inc
Ambrx Inc
amcure GmbH
Amgen Inc
AMI Onco Theranostics LLC
ANP Technologies Inc
AP Biosciences Inc
Apexigen Inc
Apollomics Inc
Arcus Biosciences Inc
Argenx SE
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Asclepiumm Taiwan Co Ltd
AsclepiX Therapeutics Inc
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Aura Biosciences Inc
Aurigene Discovery Technologies Ltd
Avalon GloboCare Corp
AVEO Oncology Inc
Aveta Biomix Inc
Avvinity Therapeutics Ltd
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Bexion Pharmaceuticals LLC
Bio-Thera Solutions Ltd
BioAtla LLC
Biohaven Pharmaceutical Holding Company Ltd
BioLineRx Ltd
Biomix Biotechnologies Co Ltd
Biomimetix JV LLC
Biomunex Pharmaceuticals
BioNTech SE

Bioven Group
BJ Bioscience Inc
Boehringer Ingelheim International GmbH
Boryung ViGenCell Inc
Boston Biomedical Inc
BrightPath Biotherapeutics Co Ltd
Bristol-Myers Squibb Co
Brooklyn ImmunoTherapeutics LLC
Cancer Therapeutics Laboratories Inc
Canget BioTekpharma LLC
CanImGuide Therapeutics AB
Cantargia AB
CarboMimetics
CEL-SCI Corp
Celldex Therapeutics Inc
Cellestar Biosciences Inc
Cello Therapeutics Inc
Cellular Biomedicine Group Inc
Celprogen Inc
Centurion BioPharma Corp
Checkmate Pharmaceuticals Inc
Checkpoint Therapeutics Inc
Chi Cheung (Shanghai) Biomedical Co Ltd
China Immunotech Co Ltd
Corvus Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
CStone Pharmaceuticals Co Ltd
Cue Biopharma Inc
Cullinan Oncology LLC
Curevac AG
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
CytImmune Sciences Inc
Cytocom Inc
Cytodyn Inc
CytoMed Therapeutics Pte Ltd
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA

DelMar Pharmaceuticals Inc
DNJ Pharma Inc
Dragonboat Biopharmaceutical (Shanghai)Co Ltd
eFFECTOR Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Elicio Therapeutics
ENB Therapeutics LLC
EnGeneIC Ltd
Enzene Biosciences Ltd
EpicentRx Inc
Etubics Corp
Eutilex Co Ltd
Exelixis Inc
Exicure Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fochon Pharma Inc
Forbius
Fujifilm Holdings Corp
G&E Corp
Galectin Therapeutics Inc
GEEN Biotechnology Inc
Geneius Biotechnology Inc
Genelux Corp
Genentech Inc
Genmab AS
Genocea Biosciences Inc
GeoVax Labs Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
GLG Pharma SA
Gliknik Inc
Glycomantra Inc
GlycoMira Therapeutics Inc
Glycotope GmbH
GT Biopharma Inc
Guangzhou Double Bioproduct Inc
Guangzhou Hanghua Bio Pharmaceutical Technology Co

Guangzhou Sinogen Pharmaceutical Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed
Hengenix Biotech Inc
Hercules Pharmaceuticals BV
Hookipa Pharma Inc
Horizon Therapeutics PLC
Hummingbird Bioscience Pte Ltd
HylaPharm
Idera Pharmaceuticals Inc
ImCheck Therapeutics SAS
Immatics Biotechnologies GmbH
ImmuneSensor Therapeutics Inc
Immunicum AB
ImmunityBio Inc
Immunocore Ltd
Immunomedics Inc
Immunomic Therapeutics Inc
Immutep Ltd
Immvira Co Ltd
IMV Inc
Incyte Corp
Infinity Pharmaceuticals Inc
Inhibrx Inc
Innate Pharma SA
Innovene
Innovent Biologics Inc
Inovio Pharmaceuticals Inc
Intensity Therapeutics Inc
InteRNA Technologies BV
Invectys SA
InxMed Shanghai Co Ltd
IO Biotech ApS
Iovance Biotherapeutics Inc
Ipsen SA
ISA Pharmaceuticals BV
iSTAT Therapeutics Inc
ISU ABXIS Co Ltd
Jacobio Pharmaceuticals Co Ltd

Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Jounce Therapeutics Inc
Juno Therapeutics Inc
Kiromic BioPharma Inc
Kitov Pharma Ltd
Komipharm International Co Ltd
Konruns Pharmaceutical Co Ltd
Kuur Therapeutics Ltd
Kymab Ltd
Kyowa Kirin Co Ltd
L.E.A.F. Pharmaceuticals LLC
Laboratoires Pierre Fabre SA
LATITUDE Pharmaceuticals Inc
Leucid Bio Ltd
LIft BioSciences Ltd
Lion TCR Pte Ltd
LipoSeuticals Inc
Luye Pharma Group Ltd
Luzitin SA
Lytix Biopharma AS
Mabion SA
MacroGenics Inc
MAIA Biotechnology Inc
Mateon Therapeutics Inc
Maverick Therapeutics Inc
MaxiVAX SA
MediciNova Inc
Medivir AB
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Mersana Therapeutics Inc
Mirati Therapeutics Inc
MiRecule Inc
MiReven Pty Ltd
Mitsubishi Tanabe Pharma Corp
Moderna Inc

Modra Pharmaceuticals BV
Molecular Partners AG
Molecular Templates Inc
Moleculin Biotech LLC
MolMed SpA
MultiVir Inc
Nanjing Iaso Biotherapeutics Co Ltd
NanoCarrier Co Ltd
NantBioScience Inc
NantKwest Inc
Natco Pharma Ltd
Nektar Therapeutics
Neonc Technologies Inc
NeoTX Therapeutics Ltd
Neumedicines Inc
NextCure Inc
NGM Biopharmaceuticals Inc
Northwest Biotherapeutics Inc
Novartis AG
Noxopharm Ltd
Ocellaris Pharma Inc
Ona Therapeutics SL
Oncolmmune Inc
Oncologie Inc
Oncology Venture A/S
Oncolys BioPharma Inc
Onconova Therapeutics Inc
Oncorus Inc
OncoSec Medical Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Onxeo SA
Otsuka Holdings Co Ltd
Oxford Vacmedix UK Ltd
PDS Biotechnology Corp
Pfizer Inc
Pharma Mar SA
Philogen SpA
Phio Pharmaceuticals Corp

Phosplatin Therapeutics LLC
PIQUR Therapeutics AG
Plexxikon Inc
Plus Therapeutics Inc
PNP Therapeutics Inc
Polaris Pharmaceuticals Inc
Potenza Therapeutics Inc
Precigen Inc
PRISM Pharma Co Ltd
Privo Technologies Inc
Protheragen Inc
PsiOxus Therapeutics Ltd
QBiotics Ltd
Qilu Pharmaceutical Co Ltd
Qilu Puget Sound Biotherapeutics Corp
Qrono Inc
R Pharm
Rakuten Medical Inc
RAPT Therapeutics Inc
RaQualia Pharma Inc
Refuge Biotechnologies Inc
Regeneron Pharmaceuticals Inc
Rimo Therapeutics Inc
Sanofi
Sareum Holdings Plc
Scancell Holdings Plc
Seattle Genetics Inc
SEEKYO Therapeutics
Selecta Biosciences Inc
Sensei Biotherapeutics Inc
Shanghai GeneChem Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Jing Ze Biotechnology Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Miracogen Inc
Shattuck Labs Inc
Shionogi & Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Sierra Oncology Inc

Sillajen Biotherapeutics
Sino Biopharmaceutical Ltd
Sinocelltech Ltd
Sirnaomics Inc
Sirona Therapeutics Inc
SL Bigen Inc
SMET Pharmaceutical Inc
Soricimed Biopharma Inc
Sotio AS
Spring Bank Pharmaceuticals Inc
SQZ Biotechnologies Co
STAT3 Therapeutics Inc
Stcube Inc
Stella Pharmaceuticals Pvt Ltd
StemMed Ltd
Sumitomo Dainippon Pharma Co Ltd
SuviCa Inc
Suzhou Max Bio-tech Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Sveikatal Inc
Synermore Biologics Co Ltd
Tactical Therapeutics Inc
Takis Srl
Tallikut Pharmaceuticals Inc
TCRCure Biotech Co Ltd
Telix Pharmaceuticals Ltd
Tempest Therapeutics Inc
Tessa Therapeutics Pte Ltd
Theralase Technologies Inc
Theravectys SA
Tolero Pharmaceuticals Inc
Torque Therapeutics Inc
TOT Biopharm Co Ltd
Transgene SA
Trovagene Inc
Turning Point Therapeutics Inc
Turnstone Biologics Inc
Tvardi Therapeutics Inc
Tyme Technologies Inc

UbiVac LLC
Vaccibody AS
Vaccinex Inc
VasGene Therapeutics Inc
Vault Pharma Inc
VCN Biosciences SL
Veana Therapeutics LLC
Vectorite Biomedical Inc
Venus Remedies Ltd
Verastem Inc
Viracta Therapeutics Inc
Viralytics Pty Ltd
Virion Therapeutics LLC
Voronoi
Vyriad Inc
Wayshine Biopharma Inc
Wuhan Binhui Biotechnology Co Ltd
Xbrane Biopharma AB
Xencor Inc
Xiangxue Life Sciences
XuanZhu Pharma Co Ltd
Xynomic Pharmaceuticals Holdings Inc
Zhejiang Yangshengtang Biotech Co Ltd
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
Zymeworks Inc

I would like to order

Product name: Head And Neck Cancer - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/HA9E6D26841EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HA9E6D26841EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970